A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
Phase 3
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: PlaceboDrug: AMR101Drug: Statin therapy
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 8179
- Registration Number
- NCT01492361
- Locations
- 🇺🇦
Amarin Investigational Site, Zaporizhzhia, Ukraine
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: AMR101 (ethyl icosapentate) - 2 g/dayDrug: AMR101 (ethyl icosapentate) - 4 g/dayDrug: Placebo
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT01047683
- Locations
- 🇺🇦
Amarin Investigational Site, Odessa, Ukraine
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: PlaceboDrug: AMR101 (ethyl icosapentate) - 2 g/dayDrug: AMR101 (ethyl icosapentate) - 4 g/day
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 702
- Registration Number
- NCT01047501
- Locations
- 🇺🇸
Amarin Investigational Site, Wauwatosa, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath